In this study, a novel heteropolysaccharide named SP90-1 with immunostimulatory and antitumor activity was purified and characterized from Spirulina platensis. SP90-1 has a molecular weight of 63.92 kDa and mainly consists of rhamnose (Rha), glucose (Glc), galactose (Gal) and glucuronic acid (GlcA), followed by the minor components Fuc and Xyl. The backbone of SP90-1 was determined to be →2)-α-d-Rhap-(1 → 2,3)-α-d-Rhap-(1 → 4)-β-d-Glcp-(1 → [3)-β-d-Rhap-(1→], with branches at the O-3 of Rha, consisting of the side chains 4-Galp and 4-GlcpA. SP90-1 was found to significantly enhance phagocytic capacity, promote the secretion of nitric oxide (NO), interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) in RAW264.7 cells, and remarkably inhibit the growth of A549 lung cancer cells. These findings demonstrate that SP90-1 could potentially be further explored for immunomodulatory biomedical applications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijbiomac.2021.12.062 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cytokine-armed pyroptosis induces antitumor immunity against diverse types of tumors.
Nat Commun
December 2024
Department of Synthetic Biology and Immunology, National Institute of Chemistry, Ljubljana, Slovenia.
Inflammasomes are defense complexes that utilize cytokines and immunogenic cell death (ICD) to stimulate the immune system against pathogens. Inspired by their dual action, we present cytokine-armed pyroptosis as a strategy for boosting immune response against diverse types of tumors. To induce pyroptosis, we utilize designed tightly regulated gasdermin D variants comprising different pore-forming capabilities and diverse modes of activation, representing a toolbox of ICD inducers.
View Article and Find Full Text PDFExamination of the potential clinical application of 5DEX-0509R, the tumor macrophage-targeting nanomedicine.
Cytokine
December 2024
Cancer Research Unit, Sumitomo Pharma Co Ltd, Osaka, Japan. Electronic address:
Toll-like receptors (TLRs) are crucial for the detection of infections and activation of downstream signaling pathways that lead to the production of pro-inflammatory cytokines and interferons. Because of their strong immunostimulatory activity, TLRs are thought to be a "double-edged sword" for systemic treatment, even in the cancer field. To solve this, we have developed dextran-based TAM targeting activator conjugate (D-TAC) technology which successfully uses tumor-associated macrophages (TAMs) to deliver the TLR7 agonist DSP-0509.
View Article and Find Full Text PDFMetals are an emerging topic in cancer immunotherapy that have shown great potential in modulating cancer immunity cycle and promoting antitumor immunity by activating the intrinsic immunostimulatory mechanisms which have been identified in recent years. The main challenge of metal-assisted immunotherapy lies in the fact that the free metals as ion forms are easily cleared during circulation, and even cause systemic metal toxicity due to the off-target effects. With the rapid development of nanomedicine, metal-based smart nanosystems (MSNs) with unique controllable structure become one of the most promising delivery carriers to solve the issue, owing to their various endogenous/external stimuli-responsiveness to release free metal ions for metalloimmunotherapy.
View Article and Find Full Text PDFCD44-targeted hyaluronic acid coated imiquimod lipid nanocapsules foster the efficacy against skin cancer: Attempt to conquer unfavorable side effects.
Int J Biol Macromol
December 2024
Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
This study was executed to mitigate imiquimod (IMQ)-side effects and promote its anticancer potential against skin cancer via encapsulation in hyaluronic acid-coated lipid nanocapsules (HA-LNCs) for targeted topical delivery. The LNCs were prepared using the phase inversion technique. Optimized LNCs formulation was gained following 2 factorial design experiment to adjust the IMQ and CTAB concentrations.
View Article and Find Full Text PDFEngineered virus-mimicking nanovaccine with lymph node-tumor dual-targeting and STING-activating capacity for robust cancer immunotherapy.
J Control Release
December 2024
School of Medical Technology, Beijing Institute of Technology, Beijing 100081, PR China. Electronic address:
Cancer vaccines have garnered considerable interest for cancer immunotherapy. However, their effectiveness is limited by inadequate proliferation, activation, and tumor infiltration of cytotoxic T lymphocytes (CTLs). Inspired by the potent immunostimulatory properties of viral components and the exposure of calreticulin during immunogenic cell death (ICD) triggered by viral infections; in this study, we describe cGAMP@vEVs, a virus-mimicking nanovaccine strategy by engineering tumor cell-derived extracellular vesicles through virus infection, which co-load both personalized and broad antigen repertoire as well as multiple immune adjuvants to potently elicit antitumor immunity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!